Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Altimmune (ALT) Return on Sales (2016 - 2024)

Historic Return on Sales for Altimmune (ALT) over the last 17 years, with Q3 2025 value amounting to 3802.8%.

  • Altimmune's Return on Sales rose 7662000.0% to 3802.8% in Q3 2025 from the same period last year, while for Sep 2025 it was 4201.65%, marking a year-over-year decrease of 22108800.0%. This contributed to the annual value of 4755.35% for FY2024, which is 45477300.0% down from last year.
  • Latest data reveals that Altimmune reported Return on Sales of 3802.8% as of Q3 2025, which was up 7662000.0% from 4429.2% recorded in Q2 2025.
  • Altimmune's 5-year Return on Sales high stood at 7.29% for Q4 2021, and its period low was 11756.5% during Q3 2022.
  • Its 5-year average for Return on Sales is 2730.64%, with a median of 2516.5% in 2022.
  • Per our database at Business Quant, Altimmune's Return on Sales crashed by -115444100bps in 2022 and then surged by 116994000bps in 2023.
  • Over the past 5 years, Altimmune's Return on Sales (Quarter) stood at 7.29% in 2021, then plummeted by -11328bps to 833.08% in 2022, then decreased by -3bps to 855.16% in 2023, then plummeted by -445bps to 4659.6% in 2024, then rose by 18bps to 3802.8% in 2025.
  • Its Return on Sales was 3802.8% in Q3 2025, compared to 4429.2% in Q2 2025 and 3915.0% in Q1 2025.